Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer

Stopped early · Phase 2

Conditions studied: Breast Cancer

In brief

RATIONALE: Dose-dense scheduling with (peg)filgrastim support may improve the clinical and pathologic complete response rate (pCR) and safety profile of single agent neoadjuvant docetaxel therapy. PURPOSE: To evaluate whether dose-dense scheduling with (peg)filgrastim support may improve the clinical and pathologic complete response rate (pCR) and safety profile of single agent neoadjuvant docetaxel therapy. To determine the changes in molecular markers that occurs with single agent docetaxel, tissue will be obtained at the end of the four cycles of docetaxel (either by repeat biopsy or definitive surgery).

Key facts

Study ID
NCT00343512
Run by
Vanderbilt-Ingram Cancer Center
People needed
34
Starts
2004-02-01
Expected to finish
2011-03-01
Last updated by the study team
2012-04-27

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.